Impact of the COVID-19 Pandemic on Central Precocious Puberty: a Retrospective Cohort Study from Turkey

Umraniye Education and Research Hospital192 enrolled

Overview

Objective: This study investigates the clinical and demographic characteristics of girls diagnosed with central precocious puberty (CPP) in the pre-pandemic and pandemic periods to assess potential changes during the COVID-19 pandemic.

Methods: A retrospective cohort study was conducted on patients admitted to the Pediatric Endocrinology Departments of two centers in Turkey. Girls treated with GnRH analogs between March 2018 and 2022 were categorized into two groups: the pre-pandemic group (2018-2020) and the pandemic group (2020-2022). Clinical, anthropometric, and hormonal data were analyzed. Patients with organic lesions, genetic conditions, or medications affecting puberty were excluded.

Study Type

OBSERVATIONAL

Enrollment

192

Conditions

COVID19- Infection with SARS-CoV-2 Virus

Eligibility

Sex: FEMALEMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria (Who Can Participate?) Girls: Tanner stage ≥2 before age 8 peak LH \> on gnrh analog test, basal Lh \>0,3 Patients with organic lesions (e.g., hypothalamo-pituitary tumors), congenital malformations, oncological diseases, neurosurgical or genetic disorders, or medications affecting puberty were excluded from the study

Locations (1)

the Pediatric Endocrinology Departments of Umraniye Training and Research Hospital

Istanbul, Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

Mean Age at Pubertal Onset

Mean Age at Pubertal Onset Description: The mean age at pubertal onset will be compared between pre-pandemic and post-pandemic periods in both girls and boys. Time Frame: At baseline. Method of Measurement: Tanner staging, LH/FSH levels, and bone age assessment.

Time frame: 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.